Literature DB >> 23161712

Interobserver agreement among pathologists for semiquantitative hormone receptor scoring in breast carcinoma.

David A Cohen1, David J Dabbs, Kristine L Cooper, Milon Amin, Terrell E Jones, Mirka W Jones, Mamatha Chivukula, Giuliana A Trucco, Rohit Bhargava.   

Abstract

The American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines recommend reporting of hormone receptor test results in a semiquantitative manner. This study used 74 resected estrogen receptor (ER)-positive invasive breast cancers to determine reproducibility of semiquantitative scoring of hormone receptors using the H-score method. Four pathologists independently scored each slide. Agreement among observers was analyzed via Fleiss κ statistics on ER and progesterone receptor (PR) categorical scores. Intraclass correlation coefficient (ICC) was used to estimate the interobserver agreement for ER and PR H-scores on a continuous scale (0-300). There was 100% agreement for categorical ER results (κ = 1) and 97% agreement (κ = 0.823, P < .001) for categorical PR results. For quantitative H-scores, ICC agreement was 0.85 (95% confidence interval [CI] = 0.79-0.90) for ER and 0.87 (95% CI = 0.82-0.92) for PR. Because the H-score provides a continuous measure of tumor hormone receptor content, we suggest universal adoption of this method.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23161712     DOI: 10.1309/AJCP6DKRND5CKVDD

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  33 in total

1.  Use of modified Magee equations and histologic criteria to predict the Oncotype DX recurrence score.

Authors:  Bradley M Turner; Kristin A Skinner; Ping Tang; Mary C Jackson; Nyrie Soukiazian; Michelle Shayne; Alissa Huston; Marilyn Ling; David G Hicks
Journal:  Mod Pathol       Date:  2015-05-01       Impact factor: 7.842

2.  Magee Equations™ and response to neoadjuvant chemotherapy in ER+/HER2-negative breast cancer: a multi-institutional study.

Authors:  Rohit Bhargava; Nicole N Esposito; Siobhan M OʹConnor; Zaibo Li; Bradley M Turner; Ioana Moisini; Aditi Ranade; Ronald P Harris; Dylan V Miller; Xiaoxian Li; Harrison Moosavi; Beth Z Clark; Adam M Brufsky; David J Dabbs
Journal:  Mod Pathol       Date:  2020-07-13       Impact factor: 7.842

3.  Axl receptor tyrosine kinase expression in breast cancer.

Authors:  Timothy M D'Alfonso; Jeffrey Hannah; Zhengming Chen; Yifang Liu; Pengbo Zhou; Sandra J Shin
Journal:  J Clin Pathol       Date:  2014-06-05       Impact factor: 3.411

4.  Real-World Outcomes Among Older Mexican Women with Breast Cancer Treated with Neoadjuvant Chemotherapy.

Authors:  Paula Cabrera-Galeana; Enrique Soto-Perez-de-Celis; Nancy Reynoso-Noveron; Cynthia Villarreal-Garza; Fernando Lara-Medina; Alberto Alvarado-Miranda; José Rodrigo Espinosa-Fernandez; Nereida Esparza-Arias; Alejandro Mohar; Juan Enrique Bargallo-Rocha
Journal:  Oncologist       Date:  2020-04-28

5.  Association of neutrophil/lymphocyte ratio and platelet/lymphocyte ratio with ER and PR in breast cancer patients and their changes after neoadjuvant chemotherapy.

Authors:  J Xu; C Ni; C Ma; L Zhang; X Jing; C Li; Y Liu; X Qu
Journal:  Clin Transl Oncol       Date:  2017-02-28       Impact factor: 3.405

6.  Magee Equation 3 predicts pathologic response to neoadjuvant systemic chemotherapy in estrogen receptor positive, HER2 negative/equivocal breast tumors.

Authors:  Daniel J Farrugia; Alessandra Landmann; Li Zhu; Emilia J Diego; Ronald R Johnson; Marguerite Bonaventura; Atilla Soran; David J Dabbs; Beth Z Clark; Shannon L Puhalla; Rachel C Jankowitz; Adam M Brufsky; Barry C Lembersky; Gretchen M Ahrendt; Priscilla F McAuliffe; Rohit Bhargava
Journal:  Mod Pathol       Date:  2017-05-26       Impact factor: 7.842

7.  A systematic comparison of three commercial estrogen receptor assays in a single clinical outcome breast cancer cohort.

Authors:  Elizabeth N Kornaga; Alexander C Klimowicz; Natalia Guggisberg; Travis Ogilvie; Don G Morris; Marc Webster; Anthony M Magliocco
Journal:  Mod Pathol       Date:  2016-04-29       Impact factor: 7.842

8.  Evaluation of the HER2 and Hormone Receptor Status in Metastatic Breast Cancer Using Cell Blocks: A Multi-Institutional Study.

Authors:  Rieko Nishimura; Yuya Murata; Kiyoshi Mori; Katsushige Yamashiro; Kazuya Kuraoka; Shu Ichihara; Kenichi Taguchi; Hiroyoshi Suzuki; Masahiro Ito; Natsumi Yamashita
Journal:  Acta Cytol       Date:  2018-05-15       Impact factor: 2.319

9.  Intratumor Heterogeneity Affects Gene Expression Profile Test Prognostic Risk Stratification in Early Breast Cancer.

Authors:  Rekha Gyanchandani; Yan Lin; Hui-Min Lin; Kristine Cooper; Daniel P Normolle; Adam Brufsky; Michael Fastuca; Whitney Crosson; Steffi Oesterreich; Nancy E Davidson; Rohit Bhargava; David J Dabbs; Adrian V Lee
Journal:  Clin Cancer Res       Date:  2016-05-16       Impact factor: 12.531

10.  Sulfasalazine modifies metabolic profiles and enhances cisplatin chemosensitivity on cholangiocarcinoma cells in in vitro and in vivo models.

Authors:  Malinee Thanee; Sureerat Padthaisong; Manida Suksawat; Hasaya Dokduang; Jutarop Phetcharaburanin; Poramate Klanrit; Attapol Titapun; Nisana Namwat; Arporn Wangwiwatsin; Prakasit Sa-Ngiamwibool; Narong Khuntikeo; Hideyuki Saya; Watcharin Loilome
Journal:  Cancer Metab       Date:  2021-03-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.